Highly Regulated Industries insights

Six what-if scenarios for regulated businesses, from a banned product to a lost processor: what breaks first, the warning signs, and the first moves.

Regulation is a variable, not a constant. How to model ranges, scenarios, triggers, and reserves for rules that keep moving.

Medical cannabis moved to Schedule III. Licensing, track-and-trace, testing, excise tax, banking, and state lines did not. What each layer still costs.

FDA authorization is product by product, and California adds its own list. How to track regulatory status by SKU and protect inventory and revenue.

Federal law narrowed the definition of hemp, starting November 12, 2026. What happens to inventory, contracts, and cash when a product stops qualifying.

Oregon and Colorado license psilocybin services, but psilocybin is still Schedule I. Break-even, capacity, and §280E, in round numbers.

A lawful product can still fail on how it is advertised, shipped, paid for, taxed, or sold. How to map every layer of your top revenue stream.

Track-and-trace, the books, and the tax return can each show a different inventory. Why they drift, what each one feeds, and the monthly fix.

Section 280E limits deductions, not cost of goods sold. What dispensaries, cultivators, and manufacturers can and cannot include in inventory cost.

Limited banking costs more than bank fees. How to add up the regulatory friction tax, follow the cash reporting rules, and build the cost into your plan.

For tobacco and nicotine, 'safer' is a regulated claim, not just a marketing word. What an unauthorized claim can cost, and the controls that prevent it.

In regulated markets, compliance looks like pure overhead. What it costs, what it buys, and how to run it like an operating function.

Medical cannabis moved to Schedule III in 2026. Adult-use did not. What that means for §280E, cost of goods sold, and your California return.